Big pharma and investors re-engage in CGTs and race to scale [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
2026 success hinging on scalable platforms, manufacturing automation, regulatory momentum and real-world commercial infrastructure. The cell and gene therapy (CGT) landscape has shifted from scientific novelty to scaled delivery in recent years and has become a revenue-producing category in the industry. Based on panels of the Cell and Gene State of the Industry Briefing event of the Alliance for Regenerative for Medicine (ARM), which took place on the 12 th of January 2026 in San Francisco, the success of CGTs depends on manufacturing, infrastructure and commercial execution as much as clinical data. CGTs have significantly transformed treatment paradigms across genetic diseases, with development efforts still concentrated in oncology, blood disorders such as sickle cell disease, haemophilia and beta-thalassaemia, and central nervous system (CNS) disorders. The commercial CGT market is solidifying and is forecast to rise through 2031, reaching $63bn, according to a report on CG
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- 2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomidePR Newswire
- Update: Market Chatter: Johnson & Johnson Convinces Court to Recalculate $1 Billion Auris Award [Yahoo! Finance]Yahoo! Finance
- Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website